De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
Tal Sella, Frederieke van Duijnhoven, Hans Wildiers, Claudio Venieri et autres
0 citationsThe Breast
Ana Fortuna
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
27Publications signalées
38Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesEstrogen and related hormone effectsCholangiocarcinoma and Gallbladder Cancer Studies
Publications récentes
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy
Ayelet Shai, Hans Wildiers, Claudio Venieri, Katarzyna Pogoda et autres
3 citationsThe Breast
Abstract P5-01-12: Subsequent Treatments After Progression On Cyclin-Dependent Kinase 4/6 Inhibitors - A Multicentric Portuguese Real-world Data Study
A.R. Freitas, Inês Eiriz, Marta Vaz Batista, Andreia Chaves et autres
0 citationsClinical Cancer Research
40eP Impact of pembrolizumab chemotherapy in persistent, recurrent, or metastatic cervical cancer: Real-world data from a multicenter study
Thalita Silva Martins, Ana Fortuna, Rita Marques, Pedro Simões et autres
1 citationESMO Open
198P Association of ovarian function suppression with distant disease-free survival in premenopausal-patients with HR+HER2+ localized breast cancer: A retrospective study in 26 sites
Ayelet Shai, Hans Wildiers, Claudio Vernieri, K. Pogoda et autres
1 citationESMO Open
Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing
Lisa Gonçalves, Helena Guedes, Ana Fortuna, Telma Maria Araújo Moura Lemos et autres
4 citationsCancers
Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy
Ayelet Shai, Hans Wildiers, Claudio Vernieri, Katarzyna Pogoda et autres
0 citationsSSRN Electronic Journal
105P Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study
André Ricardo Ribas Freitas, Inês Eiriz, Marta Vaz Batista, Carla S. Santos et autres
0 citationsESMO Open
597P Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
F.L. Simões, Fernando Luiz Affonso Fonseca, Janine Magalhães, Carlos Sousa Pinto et autres
0 citationsAnnals of Oncology
Exploring the feasibility and implications of cranioencephalic computed tomography in HER2-positive breast cancer: A pilot study
Ana Fortuna, Paulo Luz, Magda Cordeiro, Beatriz Gosálbez et autres
2 citationsHeliyon
313P Disease and treatment patterns for advanced cholangiocarcinoma: A multicentric study from Portugal
J.C.N. Gonçalves, André Ricardo Ribas Freitas, Ana Fortuna, Marcelo Bezerra de Menezes et autres
0 citationsAnnals of Oncology
4P Prognostic value of systemic inflammatory markers in GBM: Multicenter retrospective study
M.J.R.G.D.L. Ramos, CARLA PATRÍCIA DE ALMEIDA OLIVEIRA, Ana Fortuna, Ênio Ferreira et autres
0 citationsESMO Open
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.